SLA 0.00% $3.34 silk laser australia limited

latest research, page-12

  1. 56 Posts.
    Hi PeeWee,

    probably the most interesting post youve made-great article. But i have med background, so might seem irrelevant to alot of posters on this thread as Ropren is of course Approved for liver damage, next target alcohol and drug addiction/sideeffects, depression etc.

    "Simvastatin (Zocor) now a serious risk for the future of Ropren (see below)" Its these sorts of comments that get everyone in a flap. Obvious downramping as it will be years before SLA will even have time (or production capacity) to consider getting into wide scale dementia treatment. Alot more fish to fry before we even have to worry about it.

    I hold

    BB
 
watchlist Created with Sketch. Add SLA (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.